Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.19 per share.
For the full year, analysts predict loss of $ 0.95 per share.
Stock Performance
Shares of Eloxx Pharmaceuticals, Inc. traded low $ -0.02 or -0.76 percent on Wednesday, reaching $ 2.61 with volume of 39.40 thousand shares. Eloxx Pharmaceuticals, Inc. has traded high as $ 2.65 and has cracked $ 2.52 on the downward trend
The closing price of $ 2.61, representing a 82.64 % increase from the 52 week low of $ 1.44 and a 67.77 % decrease over the 52 week high of $ 8.16.
The company has a market capital of $ 104.76 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Eloxx Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.eloxxpharma.com
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel ribonucleic acid for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which has completed Phase 1 clinical trial that focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
